Skip to content

Clinical trials

Carcinoma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma Country / region: United States Clear all

401 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20014
20029
200312
20045
200514
200621
200710
200821
200920
201016
201111
201214
20139
201415
201513
201614
201719
201813
201921
202023
202117
202226
202319
202413
202518
202615

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed205
Recruiting65
Terminated62
Active, not recruiting39
Withdrawn13
Unknown status8
Not yet recruiting3
Suspended2
Enrolling by invitation2
No longer available1
Available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)26
Pfizer16
AstraZeneca13
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins13
Novartis Pharmaceuticals12
M.D. Anderson Cancer Center10
H. Lee Moffitt Cancer Center and Research Institute8
Stanford University7
Eli Lilly and Company6
Akamis Bio5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma401
Neoplasms136
Carcinoma, Non-Small-Cell Lung74
Neoplasm Metastasis60
Adenocarcinoma48
Squamous Cell Carcinoma of Head and Neck45
Lung Neoplasms42
Head and Neck Neoplasms33
Neoplasms by Site28
Oropharyngeal Neoplasms28

Trials

Showing 26 to 50 of 401. Each trial links to its page on Pharma Observatory.

301 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.